175 related articles for article (PubMed ID: 38484586)
1. Recent development of VEGFR small molecule inhibitors as anticancer agents: A patent review (2021-2023).
Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
[TBL] [Abstract][Full Text] [Related]
2. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
[TBL] [Abstract][Full Text] [Related]
3. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
[TBL] [Abstract][Full Text] [Related]
4. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
Cells; 2022 May; 11(10):. PubMed ID: 35626731
[TBL] [Abstract][Full Text] [Related]
5. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy.
Liu XJ; Zhao HC; Hou SJ; Zhang HJ; Cheng L; Yuan S; Zhang LR; Song J; Zhang SY; Chen SW
Bioorg Chem; 2023 Apr; 133():106425. PubMed ID: 36801788
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
7. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Shi L; Zhou J; Wu J; Shen Y; Li X
Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
[TBL] [Abstract][Full Text] [Related]
8. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
11. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
[TBL] [Abstract][Full Text] [Related]
13. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Nilsson MB; Giri U; Gudikote J; Tang X; Lu W; Tran H; Fan Y; Koo A; Diao L; Tong P; Wang J; Herbst R; Johnson BE; Ryan A; Webster A; Rowe P; Wistuba II; Heymach JV
Clin Cancer Res; 2016 Apr; 22(8):1940-50. PubMed ID: 26578684
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer.
Spagnuolo A; Palazzolo G; Sementa C; Gridelli C
Expert Opin Pharmacother; 2020 Mar; 21(4):491-506. PubMed ID: 31957503
[No Abstract] [Full Text] [Related]
15. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
16. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
17. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
Zhang C; Tan C; Ding H; Xin T; Jiang Y
Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.
Moradi M; Mousavi A; Emamgholipour Z; Giovannini J; Moghimi S; Peytam F; Honarmand A; Bach S; Foroumadi A
Eur J Med Chem; 2023 Nov; 259():115626. PubMed ID: 37453330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]